Zobrazeno 1 - 10
of 261
pro vyhledávání: '"Masahiro, Yokoyama"'
Autor:
Shinya Rai, Won Seog Kim, Kiyoshi Ando, Ilseung Choi, Koji Izutsu, Norifumi Tsukamoto, Masahiro Yokoyama, Kunihiro Tsukasaki, Junya Kuroda, Jun Ando, Michihiro Hidaka, Youngil Koh, Hirohiko Shibayama, Toshiki Uchida, Deok Hwan Yang, Kenji Ishitsuka, Kenichi Ishizawa, Jin Seok Kim, Hong Ghi Lee, Hironobu Minami, Hyeon Seok Eom, Mitsutoshi Kurosawa, Jae Hoon Lee, Jong Seok Lee, Won Sik Lee, Hirokazu Nagai, Takero Shindo, Dok Hyun Yoon, Shinichiro Yoshida, Mireille Gillings, Hiroshi Onogi, Kensei Tobinai
Publikováno v:
Haematologica, Vol 108, Iss 3 (2022)
Tucidinostat (formerly known as chidamide) is an orally available, novel benzamide class of histone deacetylase (HDAC) inhibitor that selectively blocks class I and class IIb HDAC. This multicenter phase IIb study aimed to investigate the efficacy an
Externí odkaz:
https://doaj.org/article/1f6b47ace5124b24847722a0557d0ba2
Autor:
Masahiro Yokoyama, Yoshiharu Kusano, Norihito Inoue, Noriko Nishimura, Yuko Mishima, Tomoyuki Nukada, Kiyohiko Hatake, Yasuhito Terui
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background A classification tree was used to analyze background factors for granulocyte colony-stimulating factor (G-CSF) preparation selection for febrile neutropenia (FN) prophylaxis in Japanese patients with non-Hodgkin B-cell lymphoma re
Externí odkaz:
https://doaj.org/article/c104cb09f17a477da0b8915bcb699586
Diffuse large B‐cell lymphoma arising immediately after completion of treatment for Hodgkin lymphoma
Publikováno v:
eJHaem, Vol 2, Iss 4, Pp 883-884 (2021)
Externí odkaz:
https://doaj.org/article/2f9fe91391c34bd586a7cfbd4c9ec766
Autor:
Wataru Munakata, Kiyoshi Ando, Masahiro Yokoyama, Noriko Fukuhara, Kazuhito Yamamoto, Suguru Fukuhara, Ken Ohmachi, Yuko Mishima, Satoshi Ichikawa, Daisuke Ogiya, Arata Aoi, Masahiro Hatsumichi, Kensei Tobinai
Publikováno v:
International Journal of Hematology. 117:553-562
Tirabrutinib is a Bruton’s tyrosine kinase inhibitor for treating B-cell malignancies. We report the final results of a Phase I study of tirabrutinib in 17 Japanese patients with B-cell malignancies. Patients were administered tirabrutinib at a dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa6f1ec50b3bdde81f77a1f3d92f25a4
https://doi.org/10.1007/s12185-022-03514-6
https://doi.org/10.1007/s12185-022-03514-6
Autor:
Kiyohiko Hatake, Kiyotsugu Kojima, Masahiro Yokoyama, Hiroaki Asai, Daisuke Ennishi, Suzuka Asai, Kengo Takeuchi, Yasuhito Terui, Yuko Matsumoto-Mishima, Natsuhiko Sugimura, Yuji Mishima
Supplementary Data from An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b60b8d491aa301bdf35dec127985fb
https://doi.org/10.1158/1078-0432.22439626.v1
https://doi.org/10.1158/1078-0432.22439626.v1
Autor:
Kiyohiko Hatake, Kiyotsugu Kojima, Masahiro Yokoyama, Hiroaki Asai, Daisuke Ennishi, Suzuka Asai, Kengo Takeuchi, Yasuhito Terui, Yuko Matsumoto-Mishima, Natsuhiko Sugimura, Yuji Mishima
Purpose: Rituximab has greatly improved the efficacy of chemotherapy regimens for CD20-positive non-Hodgkin's lymphoma. However, although several mechanisms of action of rituximab have been identified, the exact therapeutic functions of these mechani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4360bd877c3fe2326dcae2361eb06986
https://doi.org/10.1158/1078-0432.c.6517063
https://doi.org/10.1158/1078-0432.c.6517063
Autor:
Masahiro Yokoyama, Yuko Shirouchi, Norihito Inoue, Noriko Nishimura, Hideki Uryu, Yasuhito Terui, Naoko Tsuyama, Takanori Fukuta, Kengo Takeuchi, Takashi Okabe, Yuko Mishima
Publikováno v:
Leukemia & Lymphoma. 62:2141-2150
Although outcomes of transformed diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) were improved using rituximab-combined immunochemotherapy, the efficacy of subsequent rituximab maintenance (RM) remains unclear. We retrospectively
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25fc10f0a2f7a689c1c4ff2ab113c4bd
https://doi.org/10.1080/10428194.2021.1901091
https://doi.org/10.1080/10428194.2021.1901091
Autor:
Norihito Inoue, Kengo Takeuchi, Yuko Mishima, Yuko Shirouchi, Masahiro Yokoyama, Hideki Uryu, Takanori Fukuta, Naoko Tsuyama, Yasuhito Terui, Noriko Nishimura
Publikováno v:
Leukemia & Lymphoma. 62:1869-1876
Peripheral T-cell lymphoma (PTCL) is a group of aggressive lymphomas commonly treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Progression-free survival at 24 months (PFS24) constitutes a survival predictor for some lym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b678b91981f4d6a7118916e72cf42c38
https://doi.org/10.1080/10428194.2021.1894649
https://doi.org/10.1080/10428194.2021.1894649
Autor:
Yukari Hida, Kensei Tobinai, Kiyohiko Hatake, Tomohiro Kinoshita, Tomohisa Saito, Dai Maruyama, Shinichi Makita, Yasuhito Terui, Satsuki Murakami, Kazuhito Yamamoto, Yusuke Higuchi, Masahiro Yokoyama
Publikováno v:
Japanese Journal of Clinical Oncology
Objective A phase 1 dose-escalation study of polatuzumab vedotin (pola) was conducted to assess safety, pharmacokinetics and preliminary antitumor activity of pola in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Methods Pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d92325fce02686f88fa74dfbce5e17
https://doi.org/10.1093/jjco/hyaa169
https://doi.org/10.1093/jjco/hyaa169
Autor:
Norihito Inoue, Noriko Nishimura, Yasuhito Terui, Takashi Okabe, Yuji Mishima, Yuko Mishima, Masahiro Yokoyama, Hideki Uryu, Takanori Fukuta, Yuko Shirouchi, Kiyohiko Hatake
Publikováno v:
International Journal of Hematology. 113:279-284
Somatic gene mutations related to acceleration disease and clonal evolution in multiple myeloma strongly influence severe clinical outcomes. In this study, we traced the transition of somatic mutations during the clinical course of myeloma patients o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2aad2b5e2169a293f135b9641677eab
https://doi.org/10.1007/s12185-020-02979-7
https://doi.org/10.1007/s12185-020-02979-7